Abs 1559 at #ACR22 long-term efficacy of apremilast differs between oral and genital ulcers, skin lesions and joint lesions. There may be differences in the long-term efficacy of apremilast dependent on manifestation type. @RheumNow https://t.co/I8p5fd1CA1 https://t.co/XKjpIUeiah

In this study by Stoots et al, #lupus pts w/ ⬇️ CV risk (accdg to ASCVD risk calc) had significantly abn. CAC vs. controls and assoc with: 🦋Older age, ⬇️GFR, ⬆️TC&LDL, longer dse duration. More data needed but consider regular CV screens in these pts #ACR22 @RheumNow ABST#1596 https://t.co/pECZw1n6lb

What should you use as a second-line biologic in PsA patients? In pts who discontinued TNFi, switching to a different MOA led to comparable or better outcomes vs. cycling through another TNFi. Abs#1600 @RheumNow #ACR22 https://t.co/9MZPSHD7we

Spangler et al. No increased risk of MI or stroke in denosumab vs zoledronate in 170,000 patients from Optum/MarketScan. @RheumNow #ACR22 Abstr#0575 https://t.co/5fho4WBsIG https://t.co/PNCI4xJ38u

Does curcumin help maintain drug-free remission RA? Answer is No Single center RCT Curcumin vs PBO w/ MTX withdrawal = flare-free survival = median time to flare (219 d vs. 214 d) Serum curcuminoid levels not asso w/ flares https://t.co/3U6W0Iuqrq Abs#1587 #ACR22 @Rheumnow https://t.co/GwAsY7OKTX

Metabolic disorders +diet patterns PsA 👉71.9% obese 👉metabolic synd 46.9% 👉dyslipid 41.9% 👉 HTN 37.5% Diet patterns assoc Dx activity ⬇️sugar⬇️fatigue⬇️PSAID score ⬆️whole fruit ⬇️SJC ⬆️unsat fats ⬆️enthesitis DIPSA -Med/DASH diet PsA ongoing #ACR22 @RheumNow Abst1007 https://t.co/cbggEw6IZp

TOFA and MTX: which one to withdraw first? RCT in 100+ RA pts in remission after 1 yr, 1 yr follow-up Withdraw MTX grp: Remission 30% LDA 40% Withdraw TOFA grp: Remission 50% LDA 65% diff NS small sample 8 SAEs, 72% recovery https://t.co/tMnet32TWF Abs#1586 #ACR22 @Rheumnow https://t.co/PWnkWYdlGk

"Do patients care/look for telehealth in 2022?" Ben Nowell states patients have supported telehealth for access, convenience, and affordability (gas, parking, etc.) 60% of pts still like these visits. Are you doing telemed #ACR22? @RheumNow https://t.co/5fAHsp2kBD

Cycling to 2nd after 1st line TNFi in AxSpA provides ◦ Limited benefits to pts ◦ Few pts showed clinically meaningful improvement in disease severity after 6 months ◦ Less than 25% pts remained on therapy after 2 years Mease P Abs1499 https://t.co/0Txs82KRbx #ACR22 @RheumNow https://t.co/xJiIWe9yDp

Devauchelle-Pensec et al. SEMAPHORE RCT- tocilizumab in refractory PMR. TCZ treated GC dependent patients - better disease activity, reduced GC, less flare, more frequent GC-free remission @RheumNow #ACR22 Abstr#1106 https://t.co/UevgjF8di5 https://t.co/GmXqasNscp